The estimated Net Worth of Andrew C Schmidt is at least $3.89 Million dollars as of 23 August 2021. Mr Schmidt owns over 1,449 units of Guardion Health Sciences Inc stock worth over $522,324 and over the last 19 years he sold GHSI stock worth over $3,371,054.
Sign up
Mr Schmidt GHSI stock SEC Form 4 insiders trading
Mr has made over 27 trades of the Guardion Health Sciences Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he bought 1,449 units of GHSI stock worth $8,549 on 23 August 2021.
The largest trade he's ever made was selling 94,900 units of Guardion Health Sciences Inc stock on 3 November 2014 worth over $94,900. On average, Mr trades about 9,654 units every 95 days since 2005. As of 23 August 2021 he still owns at least 51,613 units of Guardion Health Sciences Inc stock.
You can see the complete history of Mr Schmidt stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Andrew C. Schmidt biography
Andrew C. Schmidt is the VP & CFO at Guardion Health Sciences Inc.
How old is Mr Schmidt?
Mr Schmidt is 59, he's been the VP & CFO of Guardion Health Sciences Inc since . There are 3 older and 3 younger executives at Guardion Health Sciences Inc. The oldest executive at Guardion Health Sciences Inc is Robert Neal Weingarten, 69, who is the Independent Chairman & Sec..
What's Mr Schmidt's mailing address?
Andrew's mailing address filed with the SEC is 3333 MICHAELSON SUITE 650, , IRVINE, CA, 92612.
Insiders trading at Guardion Health Sciences Inc
Over the last 6 years, insiders at Guardion Health Sciences Inc have traded over $1,626,803 worth of Guardion Health Sciences Inc stock and bought 131,721 units worth $845,035 . The most active insiders traders include Bradley Louis Radoff Family..., Andrew C Schmidt, and Bret Scholtes. On average, Guardion Health Sciences Inc executives and independent directors trade stock every 273 days with the average trade being worth of $625,568. The most recent stock trade was executed by Bradley Louis Radoff Family... on 26 August 2024, trading 115,540 units of GHSI stock currently worth $1,626,803.
What does Guardion Health Sciences Inc do?
by applying the latest science, technology and research, guardion health sciences (ghs) has positioned itself to address the escalating demand for solutions that promise to improve life-diminishing health problems facing the aging baby boomer generation. guardion health sciences is dedicated to applying a scientific discipline and pharmaceutical approach to the development of safe, standardized and effective condition specific solutions. using the individual and collective knowledge of the members of our science advisory board, we will advise healthcare professionals and the public on the importance of medical foods and nutrition to achieve overall good health. the company’s first medical food, lumega-z, is scientifically formulated to restore and maintain the macular protective pigment. a depleted macular pigment is a known contributor to amd. though lumega-z was created with the amd epidemic in mind, its ingredients are also thought to be beneficial for other types of eye disease (i.
What does Guardion Health Sciences Inc's logo look like?
Complete history of Mr Schmidt stock trades at Iteris, Sientra Inc, Smith Micro Software, and Guardion Health Sciences Inc
Guardion Health Sciences Inc executives and stock owners
Guardion Health Sciences Inc executives and other stock owners filed with the SEC include:
-
Dr. David W. Evans MBA, Ph.D.,
Chief Scientific Officer & Director -
Robert Neal Weingarten,
Independent Chairman & Sec. -
Dr. David W. Evans,
Chief Scientific Officer & Director -
Craig J. Sheehan,
Chief Commercial Officer -
Jeffrey Benjamin,
Chief Accounting Officer -
Andrew C. Schmidt,
VP & CFO -
Bret D. Scholtes,
Pres, CEO & Director -
Donald A Gagliano,
Director -
Mark Goldstone,
Director -
Robert N Weingarten,
Director -
Bradley Louis Radoff Family...,
-
Kelly Anderson,
Director -
David W Evans,
Chief Scientific Officer -
Michael Favish,
Chief Executive Officer -
Craig Sheehan,
Chief Commercial Officer -
Bret Scholtes,
CEO and President -
Michaela Griggs,
Director -
Janet Hall,
CEO & President